S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The single greatest medical breakthrough of all time? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The single greatest medical breakthrough of all time? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The single greatest medical breakthrough of all time? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The single greatest medical breakthrough of all time? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds

Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

$8.45
-0.10 (-1.17%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.39
$8.55
50-Day Range
$7.82
$9.48
52-Week Range
$6.78
$11.34
Volume
7.94 million shs
Average Volume
10.37 million shs
Market Capitalization
$9.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.44

Teva Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Hold
2.10 Rating Score
Upside/​Downside
23.6% Upside
$10.44 Price Target
Short Interest
Healthy
2.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-0.42%
From $2.40 to $2.39 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

829th out of 1,027 stocks

Pharmaceutical Preparations Industry

404th out of 503 stocks

TEVA stock logo

About Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock News Headlines

Teva Pharmaceutical Is Bottoming: Here's My Strategy
Teva Pharmaceuticals Is Bottoming: Here's My Strategy
Teva Finalizes Terms For Proposed Nationwide Opioid Settlement
Teva Finalizes Nationwide Opioid Settlement Terms
Teva, AbbVie finalize $6.6 billion U.S. opioid settlements
Teva slips as JPMorgan downgrades on growth concerns
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Company Calendar

Last Earnings
11/03/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/08/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
37,537
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.44
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+23.6%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
10 Analysts

Profitability

Net Income
$417 million
Pretax Margin
-14.14%

Debt

Sales & Book Value

Annual Sales
$15.88 billion
Cash Flow
$3.61 per share
Book Value
$10.19 per share

Miscellaneous

Outstanding Shares
1,110,565,000
Free Float
1,101,458,000
Market Cap
$9.38 billion
Optionable
Optionable
Beta
1.25

Key Executives

  • Mr. Kare Schultz (Age 61)
    Pres, CEO & Director
    Comp: $4.68M
  • Mr. Eliyahu Sharon Kalif (Age 49)
    Exec. VP & CFO
    Comp: $1.74M
  • Mr. Eric DrapeMr. Eric Drape (Age 60)
    Exec. VP of Global Operations
    Comp: $1.91M
  • Mr. Mark SabagMr. Mark Sabag (Age 51)
    Exec. VP of International Markets Commercial
    Comp: $1.79M
  • Dr. Sven Dethlefs Ph.D. (Age 53)
    Exec. VP of North America Commercial
    Comp: $1.72M
  • Mr. Amir Weiss (Age 45)
    Sr. VP & Chief Accounting Officer
  • Mr. Kevin C. Mannix
    Sr. VP of Investor Relations
  • Mr. David M. Stark (Age 53)
    Exec. VP & Chief Legal Officer
  • Kathleen Veit
    Sr. VP, Global Compliance & Ethics Officer
  • Mr. Eli ShaniMr. Eli Shani
    Exec. VP of Global Marketing & Portfolio













TEVA Stock - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 3 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price forecast for 2023?

10 Wall Street analysts have issued 1 year price objectives for Teva Pharmaceutical Industries' stock. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they expect the company's share price to reach $10.44 in the next twelve months. This suggests a possible upside of 23.6% from the stock's current price.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2022?

Teva Pharmaceutical Industries' stock was trading at $8.01 at the beginning of the year. Since then, TEVA stock has increased by 5.5% and is now trading at $8.45.
View the best growth stocks for 2022 here
.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our TEVA earnings forecast
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) released its quarterly earnings data on Thursday, November, 3rd. The company reported $0.56 EPS for the quarter, missing analysts' consensus estimates of $0.58 by $0.02. The business earned $3.60 billion during the quarter, compared to analyst estimates of $3.86 billion. Teva Pharmaceutical Industries had a positive trailing twelve-month return on equity of 26.97% and a negative net margin of 8.52%.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of $2.40-$2.60 for the period, compared to the consensus earnings per share estimate of $2.50. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.46 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.75%), Abrams Capital Management L.P. (2.15%), Migdal Insurance & Financial Holdings Ltd. (1.93%), Phoenix Holdings Ltd. (1.88%), State Street Corp (1.34%) and Harel Insurance Investments & Financial Services Ltd. (1.27%). Insiders that own company stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $8.45.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $9.38 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

The company employs 37,537 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.

This page (NYSE:TEVA) was last updated on 12/8/2022 by MarketBeat.com Staff